Skip to content

Royalty revenue at other companies

Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$4.07M+269%
Biogen logo
BiogenBIIB
$9.7M-11.8%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.62M
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$6.7M+123%
Vicor logo
VicorVICR
$14.97M+39.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$9.5M+4,557%

Other financials

Income statement

See full
Revenue$1.4B+14.9%
Gross profit$785.0M+14.8%
Net income$57.0M-14.9%
EPS (diluted)$0.11-15.4%

Balance sheet

See full
Cash & equivalents$428.0M-12.1%
Total debt$4.3B-1.7%
Total equity$6.5B+2.3%
Total assets$13.2B+2.2%

Cash flow

See full
Operating cash flow$13.0M+425%
CapEx$51.0M-21.5%
Free cash flow-$38.0M+44.9%

Valuation

See full
Market cap$12.1B+128%
Enterprise value$15.99B+73.1%
P/S2.5×+1.3×

Profitability

See full
Gross margin55.1%+0.2pp
Net margin-4.9%-13.6pp
FCF margin6.4%-1.4pp

Returns & leverage

See full
Return on equity-3.8%-9.9pp
Debt / equity0.7×0.0×
Current ratio2.2×-0.6×

Where this comes from

Reported directly by Elanco Animal Health Inc. in its filing.

Tagged under the XBRL concept elan:PurchaseAndSaleAgreementSoldPortionOfRoyaltyRevenue.

The official record: Elanco Animal Health Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Elanco Animal Health Inc.'s royalty revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Elanco Animal Health Inc.'s royalty revenue?
Elanco Animal Health Inc. (ELAN) reported royalty revenue of $9M in Q1 2026.
What does royalty revenue mean?
Cash received from licensing or selling rights to intellectual property.
How do you interpret royalty revenue?
Higher values indicate successful monetization of R&D and intellectual property portfolios.
How does royalty revenue compare across companies?
Highly relevant for pharmaceutical and biotech companies that frequently license out drug candidates or technologies.